Orient has reduced its holding in REMEGEN (09995) by 160,000 shares at an average price of around 84.83 Hong Kong dollars per share.
On May 19th, Orient Securities reduced its holdings of Rongchang Biotech (09995) by 160,000 shares, with an average price per share of 84.8306 Hong Kong dollars, totaling approximately 13.5729 million Hong Kong dollars.
The latest information from the Hong Kong Stock Exchange shows that on May 19, Orient reduced its holdings of REMEGEN (09995) by 160,000 shares, with an average price of 84.8306 Hong Kong dollars per share, totaling approximately 13.5729 million Hong Kong dollars. The latest number of shares held after the reduction is 10.3745 million shares, with a new holding ratio of 4.97%.
Related Articles
CF PHARMTECH (02652) invested 1.3544 million Hong Kong dollars to repurchase 67,500 shares on May 26th.
A-share Announcement Highlights | GigaDevice Semiconductor Inc. (603986.SH): Holding a small percentage of shares in Changxin Technology, the controlling shareholder's reduction plan is still being implemented.
Yes Optoelectronics (002952.SZ) controlling shareholders and major shareholders plan to reduce their combined shareholding by no more than 5.28%.
CF PHARMTECH (02652) invested 1.3544 million Hong Kong dollars to repurchase 67,500 shares on May 26th.
A-share Announcement Highlights | GigaDevice Semiconductor Inc. (603986.SH): Holding a small percentage of shares in Changxin Technology, the controlling shareholder's reduction plan is still being implemented.
Yes Optoelectronics (002952.SZ) controlling shareholders and major shareholders plan to reduce their combined shareholding by no more than 5.28%.
